Commentary: Mumps vaccines: Do we need a new one?

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 381-382

  Plotlan, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUMPS VACCINE;

ADAPTIVE IMMUNITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEMORY CELL; MUMPS; NOTE; ORCHITIS; PRIORITY JOURNAL;

ADOLESCENT; COMMUNICABLE DISEASES, EMERGING; HUMANS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84876225759     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182809dda     Document Type: Note

References (39)

1. Cortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46:1172-1180.
2. Marin M, Quinlisk P, Shimabukuro T, et al. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine. 2008;26:3601-3607.
3. CDC. Update: mumps outbreak-New York and New Jersey, June 2009-Jan-uary 2010. MMWR Morb Mortal Wkly Rep. 2010;59:125-129.
4. Vandermeulen C, Roelants M, Vermoere M, et al. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine. 2004;22:2713-2716.
5. Brockhoff HJ, Mollema L, Sonder GJ, et al. Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine. 2010;28:2932-2936.
6. Greenland K, Whelan J, Fanoy E, et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010. Vuccine. 2012;30:4676-4680.
7. Anis E, Grotto I, Moerman L, et al. Mumps outbreak in Israel's highly vaccinated society: are two doses enough? Epidemiol Infect. 2012;140:439-446.
8. Park DW, Nam MH, Kim JY, et al. Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Vaccine. 2007;25:4665-4670.
9. Bangor-Jones RD, Dowse GK, Giele CM, et al. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust. 2009;191:398-401.
10. Barskey AE, Schulte C, Rosen JB, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012;367:1704-1713.
11. Atrasheuskaya AV, Kulak MV, Rubin S, et al. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004. Clin Microbiol Infect. 2007;13:670-676.
12. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine. 2009;27:6186-6195.
13. Nójd J, Tecle T, Samuelsson A, et al. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine. 2001;19:1727-1731.
14. Kaaijk P, van der Zeijst B, Boog M, et al. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill. 2008;13:18921.
15. Heininger U, Bonhoeffer J. Interstrain antigenic variability of mumps viruses. Clin Infect Dis. 2008;46:150-151.
16. Rubin SA, Qi L, Audet SA, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198:508-515.
17. Rubin SA, Link MA, Sauder CJ, et al. Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol. 2012;86:615-620.
18. Santak M, Lang-Balija M, Ivancic-Jelecki J, et al. Antigenic differences between vaccine and circulating wild-type mumps viruses decreases neutralization capacity of vac cine-induced antibodies. Epidemiol Infect. 2012;7:1-12.
19. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055-1065.
20. Cortese MM, Barskey AE, Tegtmeier GE, et al. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis. 2011;204:1413-1422.
21. Allwinn R, Zeidler B, Steinhagen K, et al. Assessment of mumps virus-specific antibodies by different serological assays: which test correlates best with mumps immunity? Eur J Clin Microbiol Infect Dis. 2011;30:1223-1228.
22. Kontio M, Jokinen S, Paunio M, et al. Waning antiobdy levels and avidity: implications for MMR vac cine-induced protection. J Inf Dis. 2012;206:1542-1548.
23. Latner DR, McGrew M, Williams N, et al. Enzyme-linked immuno-spot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol. 2011;18:35-42.
24. Vandermeulen C, Verhoye L, Vaidya S, et al. Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice. Immunology. 2010;131:33-39.
25. Jokinen S, Osterlund P, Julkunen I, et al. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis. 2007;196:861-867.
26. Hanna-Wakim R, Yasukawa LL, Sung P, et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis. 2008;197:1669-1675.
27. Deeks SL, Lim GH, Simpson MA, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ. 2011;183:1014-1020.
28. Snijders BE, van Lier A, van de Kassteele J, et al. Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008. Vaccine. 2012;30:2999-3002.
29. Eick AA, Hu Z, Wang Z, et al. Incidence of mumps and immunity to measles, mumps and rubella among US military recruits, 2000-2004. Vaccine. 2008;26:494-501.
30. LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;199:552-560.
31. Eriksen J, Davidkin I, Kafatos G, et al. Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect 2012; 12:1-16.
32. Levine H, Ankol OE, Rozhavski V, et al. Sub-optimal prevalence of mumps antibodies in a population based study of young adults in Israel after 20 years of two dose universal vaccination policy. Vaccine. 2011;29:2785-2790.
33. Dittrich S, Hahné S, van Lier A, et al. Assessment of serological evidence for mumps virus infection in vaccinated children. Vaccine. 2011;29:9271-9275.
34. Fanoy EB, Crem er J, Ferreira JA, et al. Transmission of mumps virus from mumps-vaccinated individuals to close contacts. Vaccine. 2011;29:9551-9556.
35. Yung CF, Andrews N, Bukasa A, et al. Mumps complications and effects of mumps vaccination, England and Wales, 2002-2006. Emerging Infect Dis. 2011;17:661-667; quiz 766.
36. Hahné S, Whelan J, van Binnendijk R, et al. Mumps vaccine effectiveness against orchitis. Emerging Infect Dis. 2012;18:191-193.
37. Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis. 2008;197:1662-1668.
38. Levine H, Rishpon S, Huerta-Hartal M, et al. Preventing mumps outbreaks in confined settings: comprehensive ring vaccination as a containment strategy. Hum Vaccin. 2011;7:1389-1393.
39. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis. 2008;47:1458-1467.